Fennec Pharmaceuticals to Release Third Quarter Financials
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a notable specialty pharmaceutical company, has announced plans to unveil its third quarter financial performance. The reveal is set to occur before the U.S. financial markets open on Thursday.
What to Expect from the Conference Call
A conference call will be held the same day, allowing interested parties to dive deeper into the company’s financial results and future business strategies. This event aims to provide insights into Fennec’s operations and future prospects, as management addresses various queries during the call.
Accessing the Financial Results Conference
Attending the conference call is straightforward for interested investors and analysts. Registration is required to obtain a unique dial-in number and PIN to participate. A live webcast will also be accessible on the company’s official website, making it easy for stakeholders to follow along.
Important Details for Attendees
It’s advisable to connect to the website at least fifteen minutes prior to the call to ensure a smooth experience. A replay of the conference call will be available online for up to thirty days, allowing those who may miss the live call to catch up on important announcements.
Overview of Fennec Pharmaceuticals
Fennec Pharmaceuticals is dedicated to enhancing the lives of pediatric patients. The company focuses on developing and commercializing its innovative product, PEDMARK, aimed at substantially reducing the risk of platinum-induced ototoxicity in children.
Recent Approvals and Market Impact
PEDMARK has achieved significant milestones, including receiving FDA approval in September, European Commission approval in June, and U.K. approval shortly thereafter. These approvals underscore the extensive efforts Fennec has undertaken to ensure its product reaches those in need, while also receiving Orphan Drug Exclusivity in the United States.
Company Relations and Contact Information
To learn more about the innovations and developments at Fennec Pharmaceuticals, please visit their official website. For direct communication, the company provides contact information for both investor relations and corporate media inquiries.
Connect with Fennec Pharmaceuticals
Individuals interested in discussing business opportunities or seeking further information may reach out to:
Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299
Corporate and Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com
Frequently Asked Questions
When is Fennec Pharmaceuticals releasing their Q3 results?
The third quarter financial results will be shared on November 7, 2024.
How can I listen to the financial results conference call?
You can register online to receive access details for the conference call scheduled for 8:30 a.m. Eastern Time.
What is PEDMARK?
PEDMARK is a specialty product developed by Fennec Pharmaceuticals designed to minimize the risk of hearing loss in young patients undergoing treatment with platinum-based chemotherapy.
What approvals has PEDMARK received?
PEDMARK has received several key approvals, including from the FDA, European Commission, and the U.K. health authorities, enhancing its market position.
How can investors reach Fennec Pharmaceuticals?
Investors can contact Robert Andrade, the Chief Financial Officer, for queries related to financial performance and investor relations.
